Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKinsey
Harvard Business School
McKesson
Moodys

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

ANTARA (MICRONIZED) Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Antara (micronized), and what generic alternatives are available?

Antara (micronized) is a drug marketed by Lupin Atlantis and is included in one NDA. There are four patents protecting this drug.

This drug has ninety-six patent family members in thirty-eight countries.

The generic ingredient in ANTARA (MICRONIZED) is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

US ANDA Litigation and Generic Entry Outlook for Antara (micronized)

A generic version of ANTARA (MICRONIZED) was approved as fenofibrate by RHODES PHARMS on January 28th, 2020.

  Start Trial

Summary for ANTARA (MICRONIZED)
International Patents:96
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 114
Patent Applications: 5,892
Formulation / Manufacturing:see details
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for ANTARA (MICRONIZED)
DailyMed Link:ANTARA (MICRONIZED) at DailyMed
Drug patent expirations by year for ANTARA (MICRONIZED)
Recent Litigation for ANTARA (MICRONIZED)

Identify potential future generic entrants

District Court Litigation
Case NameDate
Arabella Petroleum Company, LLC2015-07-10
Lupin Atlantis Holdings SA v. Apotex Inc.2011-06-07
In Re: FENOFIBRATE PATENT LITIGATION2011-05-23

See all ANTARA (MICRONIZED) litigation

Pharmacology for ANTARA (MICRONIZED)
Drug ClassPeroxisome Proliferator Receptor alpha Agonist
Synonyms for ANTARA (MICRONIZED)
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid,1-methylethylester
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methyl-ethyl ester
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoicacidisopropylester
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid Isopropyl Ester
2-[4-[(4-chlorophenyl)-oxomethyl]phenoxy]-2-methylpropanoic acid propan-2-yl ester
28073-EP2272825A2
28073-EP2272841A1
28073-EP2277565A2
28073-EP2277566A2
28073-EP2277567A1
28073-EP2277568A2
28073-EP2277569A2
28073-EP2277570A2
28073-EP2287163A1
28073-EP2287165A2
28073-EP2287166A2
28073-EP2292280A1
28073-EP2292620A2
28073-EP2295409A1
28073-EP2298742A1
28073-EP2298776A1
28073-EP2301923A1
28073-EP2301936A1
28073-EP2305678A1
28073-EP2314588A1
49562-28-9
562F289
A827746
AB00052196
AB00052196_17
AB00052196_18
AB00052196-15
AB00052196-16
AB0012237
AB03716
AB2000298
AC-4227
AC1L1FPK
AJ-23609
AKOS005107777
ALBB-028958
AN-9654
Ankebin
Antara
Antara (TN)
ANW-41658
API0003184
API0025994
API0026002
API0026009
AX8021009
BC202978
BCP21243
BDBM50085042
BG0483
BIDD:GT0574
BPBio1_000166
BRD-K50388907-001-05-6
BRD-K50388907-001-18-9
BRD-K50388907-001-20-5
BRN 2062462
BSPBio_000150
BSPBio_003162
C-20905
C07586
C20H21ClO4
CAS-49562-28-9
CC-28385
CCG-38996
CCRIS 7282
CHEBI:5001
CHEMBL672
CIP-Fenofibrate
CPD000058299
CS-0892
CTK8B3039
D00565
DB01039
DivK1c_000557
DSSTox_CID_9874
DSSTox_GSID_29874
DSSTox_RID_78828
DTXSID2029874
EBD45918
EC 256-376-3
EINECS 256-376-3
Elasterate
Elasterin
EU-0100486
F 6020
F0674
Fenobrate
fenofibrate
Fenofibrate (JAN/INN)
FENOFIBRATE (MICRONIZED)
FENOFIBRATE (MICRONIZED) (fenofibrate
Fenofibrate (Tricor, Trilipix)
Fenofibrate [INN:BAN]
Fenofibrate [USAN:USP:INN:BAN]
Fenofibrate IDD-P
Fenofibrate, >=99%, powder
Fenofibrate, 98%
Fenofibrate, analytical reference material
Fenofibrate, European Pharmacopoeia (EP) Reference Standard
Fenofibrate, Pharmaceutical Secondary Standard; Certified Reference Material
Fenofibrate, United States Pharmacopeia (USP) Reference Standard
Fenofibrate,(S)
fenofibrate;
Fenofibrato
Fenofibrato [INN-Spanish]
Fenofibratum
Fenofibratum [INN-Latin]
Fenogal
Fenoglide
Fenomax
Fenotard
Fibricor
Finofibrate
FNF
FT-0626400
FT-0654669
Fulcro
GP4850
GRS-027
GTPL7186
HMS1568H12
HMS1921B17
HMS2090G20
HMS2092B05
HMS2095H12
HMS2231B14
HMS3259K03
HMS3261B13
HMS3369M13
HMS3649D20
HMS3655K12
HMS3712H12
HMS501L19
HSDB 7736
HY-17356
I06-0048
IDI1_000557
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl (4''-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
Isopropyl 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionate
Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
J10318
K-9221
KBio1_000557
KBio2_001730
KBio2_004298
KBio2_006866
KBio3_002382
KBioGR_000706
KBioSS_001730
KS-00000655
LCP-Feno
LCP-FenoChol
LF 178
LF-178
Lipanthyl
Lipantil
Lipantil (TN)
Lipidex
Lipidil
Lipidil Micro
Lipidil Supra
Lipifen
Lipirex
Lipoclar
Lipofen
Lipofen (TN)
Lipofene
Liposit
Lipsin
Lofibra
Lopac-F-6020
Lopac0_000486
LP00486
LS-121256
Luxacor
MCULE-9460650238
methylethyl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate
MFCD00133314
MLS000028515
MLS001148191
MLS002548878
MolPort-002-887-051
MS-2223
NC00452
NCGC00015437-01
NCGC00015437-02
NCGC00015437-03
NCGC00015437-04
NCGC00015437-05
NCGC00015437-06
NCGC00015437-07
NCGC00015437-08
NCGC00015437-09
NCGC00015437-10
NCGC00015437-11
NCGC00015437-12
NCGC00015437-13
NCGC00015437-14
NCGC00015437-16
NCGC00015437-17
NCGC00021475-03
NCGC00021475-04
NCGC00021475-05
NCGC00021475-06
NCGC00021475-07
NCGC00021475-08
NCGC00253945-01
NCGC00261171-01
NINDS_000557
Nolipax
NSC 281319
NSC-281319
NSC-757822
NSC281319
NSC757822
Opera_ID_328
Pharmakon1600-01501010
Pharmavit
Phenofibrate
Prestwick_217
Prestwick0_000275
Prestwick1_000275
Prestwick2_000275
Prestwick3_000275
Procetofen
Procetofene
Procetoken
Proctofene
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
propan-2-yl 2-[4-(4-chlorophenyl)carbonylphenoxy]-2-methyl-propanoate
propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate
Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester
Protolipan
PubChem17489
Q-201111
s1794
SAM002264613
SBB037926
SBI-0050470.P003
SCHEMBL4670
Secalip
Sedufen
SMR000058299
SPBio_001380
SPBio_002369
Spectrum_001250
SPECTRUM1501010
Spectrum2_001390
Spectrum3_001431
Spectrum4_000413
Spectrum5_001479
SR-01000000091
SR-01000000091-16
SR-01000000091-2
SR-01000000091-5
SR-01000000091-6
SR-01000000091-8
ST085313
Supralip
SW196525-4
TC-130403
TL8003296
Tox21_110147
Tox21_110147_1
Tox21_300151
Tox21_500486
Tricor
TRICOR (MICRONIZED)
Tricor (TN)
Triglide
Triglide (TN)
U202363UOS
UNII-U202363UOS
YMTINGFKWWXKFG-UHFFFAOYSA-N
Z2768724415
ZB014484
ZINC584092
ZX-AN079771
Paragraph IV (Patent) Challenges for ANTARA (MICRONIZED)
Tradename Dosage Ingredient NDA Submissiondate
ANTARA (MICRONIZED) CAPSULE;ORAL fenofibrate 021695 2008-09-15

US Patents and Regulatory Information for ANTARA (MICRONIZED)

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-004 Oct 18, 2013 RX Yes No   Start Trial   Start Trial   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-005 Oct 18, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 AB RX Yes No   Start Trial   Start Trial   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-002 Nov 30, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 AB RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 AB RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Expired US Patents for ANTARA (MICRONIZED)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004   Start Trial   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004   Start Trial   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-002 Nov 30, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKesson
Moodys
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
 NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews